Eric Venker
President bij ROIVANT SCIENCES LTD.
Vermogen: 5 M $ op 31-03-2024
Profiel
Momenteel is Eric Venker Co-President & Chief Operating Officer bij Roivant Sciences Ltd., President & Chief Operating Officer bij Roivant Sciences, Inc. en Co-President & Chief Operating Officer bij Roivant Sciences GmbH (beide zijn dochterondernemingen van Roivant Sciences Ltd.) en Co-President & Chief Operating Officer bij Montes Archimedes Acquisition Corp. Eric Venker zit ook in de raad van bestuur van Arbutus Biopharma Corp., Sio Gene Therapies, Inc., Aruvant Sciences, Inc. en Immunovant, Inc. Voordien bekleedde hij de functie van voorzitter van de Raad voor Kwaliteit van het Huispersoneel van het Columbia University Medical Center. Eric Venker behaalde een doctoraat aan de Yale School of Medicine en een doctoraat aan het St. Louis College of Pharmacy.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ROIVANT SCIENCES LTD.
0.06% | 20-03-2024 | 500 202 ( 0.06% ) | 5 M $ | 31-03-2024 |
Actieve functies van Eric Venker
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMUNOVANT, INC. | Director/Board Member | 18-02-2020 |
| ROIVANT SCIENCES LTD. | President | 01-01-2021 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | President | 01-01-2021 |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Director/Board Member | - |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Chief Operating Officer | - |
| Roivant Social Ventures, Inc. | Director/Board Member | 01-01-2014 |
Eerdere bekende functies van Eric Venker
| Bedrijven | Functie | Einde |
|---|---|---|
| SIO GENE THERAPIES INC. | Director/Board Member | 05-04-2023 |
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 25-05-2022 |
| ROIVANT SCIENCES LTD. | President | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van Eric Venker
| St. Louis College of Pharmacy | Doctorate Degree |
| Yale School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| ROIVANT SCIENCES LTD. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Montes Archimedes Acquisition Corp operates as a blank check company. It is formed for the business purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded James C. Momtazee and Maria C. Walker on July 6, 2020 and is headquartered in Menlo Park, CA. | Finance |
| Roivant Social Ventures, Inc. |
